| Symbol | ARQT |
|---|---|
| Name | ARCUTIS BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3027 TOWNSGATE ROAD,SUITE 300, WESTLAKE VILLAGE, California, 91361, United States |
| Telephone | +1 805 418-5006 |
| Fax | — |
| — | |
| Website | https://www.arcutis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001787306 |
| Description | Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The companys lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. Additional info from NASDAQ: |
2026-07-17 20:07
Director Peetz Christopher 🟢 acquired 38.8K shares (2 derivative) of Arcutis Biotherapeutics, Inc. (ARQT) at $27.78 Transaction Date: Jul 15, 2026 | Filing ID: 048655
Read more
2026-07-17 20:01
Director Welgus Howard G. 🟡 adjusted position in 4.7K shares (3 derivative) of Arcutis Biotherapeutics, Inc. (ARQT) at $26.91 Transaction Date: Jul 15, 2026 | Filing ID: 048641
Read more
2026-07-17 17:05
New Form 3 - Arcutis Biotherapeutics, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001628280-26-048647 <b>Size:</b> 362 KB
Read more
2026-07-16 20:25
(75% Positive) ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Provides Update on time for Arcutis
Read more
2026-07-15 20:01
📋 Howard Welgus (Director) plans to sell 5K shares of Arcutis Biotherapeutics, Inc. (at $26.91 each, total $127K) Filed: Jul 15, 2026 | ID: 048326
Read more
2026-07-15 20:00
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Read more
2026-07-08 12:00
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
Read more
2026-07-02 20:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-30 13:15
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07683806 | Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrh… | Phase3 | Seborrheic Dermatitis | Not_Yet_Recruiting | 2026-08-24 | 2027-08-03 | ClinicalTrials.gov |
| NCT07453602 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | Phase1 | Atopic Dermatitis (AD) | Recruiting | 2026-03-02 | 2028-04-01 | ClinicalTrials.gov |
| NCT07340216 | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatr… | Phase1 | Psoriasis | Completed | 2025-12-15 | 2026-04-30 | ClinicalTrials.gov |
| NCT07077902 | A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hi… | Phase2 | Hidradenitis Suppurativa | Recruiting | 2025-09-25 | 2026-09-01 | ClinicalTrials.gov |
| NCT07105254 | An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of … | Phase2 | Non-segmental Vitiligo | Recruiting | 2025-08-01 | 2026-06-15 | ClinicalTrials.gov |
| NCT06998056 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2… | Phase2 | Atopic Dermatitis (Eczema) | Completed | 2025-06-09 | 2025-12-04 | ClinicalTrials.gov |
| NCT05028582 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | Phase3 | Scalp Psoriasis | Completed | 2021-08-24 | 2022-06-03 | ClinicalTrials.gov |
| NCT04973228 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Managemen… | Phase3 | Seborrheic Dermatitis | Completed | 2021-07-08 | 2022-04-06 | ClinicalTrials.gov |
| NCT04845620 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatit… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-04-07 | 2023-06-01 | ClinicalTrials.gov |
| NCT04811131 | Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial… | Phase2 | Vitiligo | Terminated | 2021-03-04 | 2021-08-09 | ClinicalTrials.gov |
| NCT04746911 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Ps… | Phase2 | Psoriasis | Completed | 2021-03-01 | 2022-05-11 | ClinicalTrials.gov |
| NCT04804605 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Manageme… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-02-25 | 2024-05-28 | ClinicalTrials.gov |
| NCT04773600 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatit… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-02-24 | 2022-09-29 | ClinicalTrials.gov |
| NCT04773587 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatit… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-01-27 | 2022-08-30 | ClinicalTrials.gov |
| NCT04655313 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Ps… | Phase2 | Psoriasis | Completed | 2020-11-30 | 2022-01-12 | ClinicalTrials.gov |
| NCT04445987 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase2 | Seborrheic Dermatitis | Completed | 2020-06-12 | 2022-11-19 | ClinicalTrials.gov |
| NCT04378569 | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema | Phase1 | Chronic Hand Eczema | Completed | 2020-04-20 | 2021-02-24 | ClinicalTrials.gov |
| NCT04279119 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults … | Phase1 | Plaque Psoriasis | Completed | 2020-03-10 | 2021-03-25 | ClinicalTrials.gov |
| NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Manageme… | Phase3 | Chronic Plaque Psoriasis | Completed | 2020-02-12 | 2024-01-22 | ClinicalTrials.gov |
| NCT04128007 | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp… | Phase2 | Plaque Psoriasis | Completed | 2020-01-13 | 2020-09-25 | ClinicalTrials.gov |
| NCT04156191 | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adoles… | Phase1 | Atopic Dermatitis (Eczema) | Completed | 2019-12-23 | 2023-05-02 | ClinicalTrials.gov |
| NCT04211363 | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Phase3 | Chronic Plaque Psoriasis | Completed | 2019-12-20 | 2020-11-16 | ClinicalTrials.gov |
| NCT04211389 | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Pso… | Phase3 | Chronic Plaque Psoriasis | Completed | 2019-12-17 | 2020-11-23 | ClinicalTrials.gov |
| NCT04091646 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase2 | Seborrheic Dermatitis | Completed | 2019-12-04 | 2020-08-21 | ClinicalTrials.gov |
| NCT03916081 | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Derm… | Phase2 | Atopic Dermatitis | Completed | 2019-05-31 | 2019-11-04 | ClinicalTrials.gov |
| NCT03764475 | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psorias… | Phase2 | Plaque Psoriasis | Completed | 2018-12-18 | 2020-10-08 | ClinicalTrials.gov |
| NCT03638258 | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chr… | Phase2 | Plaque Psoriasis | Completed | 2018-09-21 | 2019-05-29 | ClinicalTrials.gov |
| NCT03392168 | Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to M… | Phase1 | Psoriasis | Completed | 2017-12-11 | 2018-05-02 | ClinicalTrials.gov |
Total clinical trials: 28
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle foam | Other | Phase PHASE3 | Seborrheic Dermatitis | NOT_YET_RECRUITING | NCT07683806 |
| Roflumilast Foam 0.3% | Other | Phase PHASE3 | Seborrheic Dermatitis | NOT_YET_RECRUITING | NCT07683806 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT07340216 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT07340216 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT07340216 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT07340216 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT07340216 |
| Vehicle Foam | Other | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| Roflumilast Foam 0.3% | Other | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| ARQ-151- cream 0.3% | Other | Phase PHASE1 | Plaque Psoriasis | COMPLETED | NCT04279119 |
| ARQ-151 vehicle cream | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03392168 |
| ARQ-151 cream 0.15% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03392168 |
| ARQ-151 cream 0.5% | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT03392168 |
| Roflumilast | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03764475 |
| Vehicle Cream | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03638258 |
| Roflumilast Cream 0.15% | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03638258 |
| Roflumilast Cream 0.3% | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03638258 |
| Vehicle foam | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| Roflumilast foam 0.3% | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| ARQ-151 vehicle cream | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| ARQ-151 0.3% cream | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| Vehicle Cream | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211363 |
| Roflumilast 0.3% cream | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211363 |
| Vehicle Cream | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT03916081 |
| Roflumilast Cream 0.15% | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT03916081 |
| Roflumilast Cream 0.05% | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT03916081 |
| ARQ-151 cream 0.3% | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT04746911 |
| Vehicle foam | Other | Phase PHASE2 | Seborrheic Dermatitis | COMPLETED | NCT04091646 |
| Roflumilast Foam 0.3% | Other | Phase PHASE2 | Seborrheic Dermatitis | COMPLETED | NCT04091646 |
| ARQ-151 cream 0.05% | Other | Phase PHASE1 | Atopic Dermatitis (Eczema) | COMPLETED | NCT04156191 |
| ARQ-151 cream 0.15% | Other | Phase PHASE1 | Atopic Dermatitis (Eczema) | COMPLETED | NCT04156191 |
| ARQ-151 cream 0.3% | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT04655313 |
| Vehicle Foam | Other | Phase PHASE3 | Seborrheic Dermatitis | COMPLETED | NCT04973228 |
| Roflumilast Foam | Other | Phase PHASE3 | Seborrheic Dermatitis | COMPLETED | NCT04973228 |
| ARQ-252 Vehicle Cream | Other | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.1% | Other | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.3% | Other | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-154 | Other | Phase PHASE2 | Seborrheic Dermatitis | COMPLETED | NCT04445987 |
| NB-UVB phototherapy sham treatment | Drug | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| NB-UVB phototherapy active treatment | Drug | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-252 Vehicle cream | Other | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-252 cream 0.3% | Other | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| Vehicle cream | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| Roflumilast Cream | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773587 |
| Roflumilast Cream 0.15% | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773587 |
| Topical roflumilast | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04286607 |
| Roflumilast topical 0.3% foam | Other | Phase PHASE2 | Non-segmental Vitiligo | RECRUITING | NCT07105254 |
| ARQ-151 cream 0.05% | Other | Phase PHASE2 | Atopic Dermatitis (Eczema) | COMPLETED | NCT06998056 |
| Topical roflumilast 0.3% foam | Other | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07077902 |
| Vehicle Cream | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| Roflumilast Cream 0.05% | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Other | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04804605 |
| ARQ-154 Foam 0.3% | Other | Phase PHASE1 | Psoriasis | RECRUITING | NCT07340216 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | Other | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| Placebo | DRUG | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | BIOLOGICAL | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | DRUG | Phase PHASE1 | Psoriasis | RECRUITING | NCT07340216 |
| Roflumilast topical 0.3% foam | DRUG | Phase PHASE2 | Non-segmental Vitiligo | RECRUITING | NCT07105254 |
| Topical roflumilast 0.3% foam | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07077902 |
| Vehicle Foam | DRUG | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| Roflumilast Foam | DRUG | Phase PHASE3 | Seborrheic Dermatitis | COMPLETED | NCT04973228 |
| NB-UVB phototherapy sham treatment | DEVICE | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| NB-UVB phototherapy active treatment | DEVICE | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-252 Vehicle cream | DRUG | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04804605 |
| Vehicle cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| Roflumilast Cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| ARQ-151 cream 0.3% | DRUG | Phase PHASE2 | Psoriasis | COMPLETED | NCT04746911 |
| ARQ-154 | DRUG | Phase PHASE2 | Seborrheic Dermatitis | COMPLETED | NCT04445987 |
| ARQ-252 Vehicle Cream | DRUG | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.1% | DRUG | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.3% | DRUG | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| Topical roflumilast | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04286607 |
| ARQ-151- cream 0.3% | DRUG | Phase PHASE1 | Plaque Psoriasis | COMPLETED | NCT04279119 |
| ARQ-151 0.3% cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| Roflumilast 0.3% cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211363 |
| ARQ-151 cream 0.05% | DRUG | Phase PHASE2 | Atopic Dermatitis (Eczema) | COMPLETED | NCT06998056 |
| Roflumilast foam 0.3% | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| Vehicle foam | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| Roflumilast Foam 0.3% | DRUG | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| Roflumilast Cream 0.05% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| Roflumilast | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03764475 |
| Vehicle Cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| Roflumilast Cream 0.15% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773587 |
| Roflumilast Cream 0.3% | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03638258 |
| ARQ-151 vehicle cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| ARQ-151 cream 0.15% | DRUG | Phase PHASE1 | Atopic Dermatitis (Eczema) | COMPLETED | NCT04156191 |
| ARQ-151 cream 0.5% | DRUG | Phase PHASE1 | Psoriasis | COMPLETED | NCT03392168 |
Total products: 100